Association between CYP metabolizer phenotypes and selective serotonin reuptake inhibitors induced weight gain: a retrospective cohort study

Maria L. Ricardo-Silgado, Sneha Singh, Lizeth Cifuentes, Paul A. Decker, Daniel Gonzalez-Izundegui, Ann M. Moyer, Maria D. Hurtado, Michael Camilleri, Suzette J. Bielinski, Andres Acosta

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Prescription medications such as selective serotonin reuptake inhibitors (SSRIs), commonly used to treat depression, are associated with weight gain. The role of pharmacogenomics in predicting SSRI-induced weight gain is unclear. Methods: In this retrospective cohort study from participants in the Mayo Clinic RIGHT study who were prescribed citalopram, paroxetine, sertraline, or fluoxetine, our aim was to evaluate the association of metabolizer phenotype and total body weight after 6 months of SSRIs initiation. We evaluated the metabolizer phenotypes (poor/intermediate, normal, and rapid/ultra-rapid) of the cytochromes P450 enzymes genes: CYP2C9, CYP2C19, and CYP2D6 known to influence the metabolism of SSRI medications: CYP2C19 for citalopram, CYP2D6 for paroxetine, CYP2D6 and CYP2C19 for sertraline, and CYP2D6 and CYP2C9 fluoxetine. In addition, we assessed the association of metabolizer phenotype and total body weight change at six months following SSRI prescription using parametric analysis of covariance adjusted for baseline body weight and multivariate regression models. Results: CYP2C19 poor/intermediate metabolizers prescribed citalopram gained significantly more weight than normal or rapid/ultra-rapid metabolizers at 6 months (TBWG %: 2.6 [95% CI 1.3—4.1] vs. 0.4 [95% CI -0.5 – 1.3] vs. -0.1 [-95% CI -1.5—1.1]; p = 0.001). No significant differences in weight outcomes at six months of treatment with paroxetine, sertraline, or fluoxetine were observed by metabolizer status. Conclusions: Weight gain observed with citalopram may be mediated by CYP2C19 metabolizer status.

Original languageEnglish (US)
Article number261
JournalBMC Medicine
Volume20
Issue number1
DOIs
StatePublished - Dec 2022

Keywords

  • CYP metabolizer phenotypes
  • Pharmacogenomics
  • Weight gain

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Association between CYP metabolizer phenotypes and selective serotonin reuptake inhibitors induced weight gain: a retrospective cohort study'. Together they form a unique fingerprint.

Cite this